Comparing a new drug combo for advanced lung cancer with a specific gene change
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV or recurrent non-small cell lung cancer that has spread.
- Your tumor has a specific gene change called homozygous MTAP deletion or loss.
- You are in good enough health to be up and about (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have not had any prior cancer treatment for your advanced lung cancer.
- If your lung cancer is not of the squamous type, you must not have another gene change for which a standard treatment is available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
This study tests a combination of two experimental drugs (navlimetostat and pumitamig) for advanced non-small cell lung cancer in patients whose tumors have a specific genetic change called MTAP loss. The drugs are designed to attack cancer cells in a new way and may help patients whose cancer has stopped responding to previous treatments.
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Hear when a new Metastatic Non-small Cell Lung Cancer With MTAP Deletion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.